Kanai T, Monden M, Takeda T, Gotoh M, Sakon M, Umeshita K, Hasuike Y, Sakita I, Nakano H, Yoshida T
Dept. of Surgery II, Osaka University Medical School.
Gan To Kagaku Ryoho. 1993 Aug;20(11):1457-60.
Tumor infiltrating lymphocytes (TIL) and peripheral blood lymphocytes (PBL) were isolated from 5 patients with multiple hepatocellular carcinoma (HCC) and with metastatic liver tumor. Proliferation of lymphocytes was observed following addition of interleukin-2 (700 JRU/ml) into the culture media. After analysis of LAK cells by FACS, the antitumor activities were examined. Higher levels of cytotoxic activity against tumor cells (K 562 and Daudi) have continued during the culture period ranging from 2 to 5 weeks. Adoptive immunotherapy was performed using TIL-LAK and PBL-LAK via hepatic artery for three patients with HCC and one patient with metastatic tumor. The average number of administered lymphocytes was 1 x 10(9). Reduction of tumor size was observed after this therapy, which caused no severe side effects exclusive of high fever and pleural effusion. Our results indicate that the treatment using lymphokine activated killer cells and interleukin-2 may be a promising modality for patients with multiple HCC.
从5例多发性肝细胞癌（HCC）和肝转移瘤患者中分离出肿瘤浸润淋巴细胞（TIL）和外周血淋巴细胞（PBL）。向培养基中加入白细胞介素-2（700 JRU/ml）后观察淋巴细胞的增殖情况。通过流式细胞术分析LAK细胞后，检测其抗肿瘤活性。在2至5周的培养期内，对肿瘤细胞（K562和Daudi）的细胞毒性活性一直保持较高水平。对3例HCC患者和1例转移瘤患者通过肝动脉进行TIL-LAK和PBL-LAK过继免疫治疗。淋巴细胞的平均给药数量为1×10⁹。该治疗后观察到肿瘤体积缩小，除高热和胸腔积液外未引起严重副作用。我们的结果表明，使用淋巴因子激活的杀伤细胞和白细胞介素-2进行治疗可能是多发性HCC患者的一种有前景的治疗方式。
